Elevated creatine kinase levels with second-generation antipsychotics

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 23, Issue 3, 2011, Pages

  Agarkar, Smita ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOZAPINE; CREATINE KINASE; VALPROIC ACID; ZIPRASIDONE;

ADULT; BLOOD CELL COUNT; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HUMAN; LETTER; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RHABDOMYOLYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT;

EID: 80054980506     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/jnp.23.3.jnpe49     Document Type: Letter

References (5)

1. Manor I, Hermesh H, Valevski A, et al: Recurrence pattern of serum creatine phosphokinase levels in repeated acute psychosis. Biol Psychiatry 1998; 43:288-292
2. Meltzer HY, Cola PA, Parsa M: Marked elevations of serum creatinine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacol-ogy 1996; 15:395-405
3. Cervellin G, Comelli I, Lippi G: Rhabdo-myolysis: historical background, clinical, diagnostic, and therapeutic features. Clin Chem Lab Med 2010; 48:749-756
4. Melkersson K: Serum creatine kinase levels in chronic psychosis patients: a comparison between atypical and conventional antipsychotics. Prog Neuropsy-chopharmacol Biol Psychiatry 2006; 30:1277-1282; E-pub Jun 23, 2006
5. Hermesh H, Manor I, Shiloh R, et al: High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. Clin Psychopharmacol 2002; 22:252-256